.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
AstraZeneca
Johnson and Johnson
Covington
Cerilliant
McKesson
Julphar
Queensland Health
Medtronic
Chubb

Generated: July 25, 2017

DrugPatentWatch Database Preview

MEVACOR Drug Profile

« Back to Dashboard

What is the patent landscape for Mevacor, and what generic Mevacor alternatives are available?

Mevacor is a drug marketed by Merck and is included in one NDA.

The generic ingredient in MEVACOR is lovastatin. There are thirty-three drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

Summary for Tradename: MEVACOR

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list66
Clinical Trials: see list12
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEVACOR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-002Mar 28, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-003Aug 31, 1987DISCNYesNo► Subscribe► Subscribe► Subscribe
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-004Dec 14, 1988DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MEVACOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-002Mar 28, 1991► Subscribe► Subscribe
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-004Dec 14, 1988► Subscribe► Subscribe
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-003Aug 31, 1987► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
US Army
Johnson and Johnson
Deloitte
Argus Health
Cerilliant
Dow
Daiichi Sankyo
Chinese Patent Office
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot